8432 Stock Overview
Develops and markets pharmaceutical products in Taiwan and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
TSH Biopharm Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$64.70 |
| 52 Week High | NT$71.10 |
| 52 Week Low | NT$48.25 |
| Beta | 0.22 |
| 11 Month Change | 8.74% |
| 3 Month Change | 8.92% |
| 1 Year Change | 18.07% |
| 33 Year Change | 46.05% |
| 5 Year Change | -20.02% |
| Change since IPO | 11.71% |
Recent News & Updates
Shareholder Returns
| 8432 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.2% | -0.3% | -2.4% |
| 1Y | 18.1% | 11.6% | 36.2% |
Return vs Industry: 8432 exceeded the TW Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: 8432 underperformed the TW Market which returned 36.2% over the past year.
Price Volatility
| 8432 volatility | |
|---|---|
| 8432 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.9% |
Stable Share Price: 8432 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 8432's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 76 | Sze-Yuan Yang | www.tshbiopharm.com |
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan and Asia. It offers products for cardiovascular, central nervous, gastrointestinal, and others. The company was founded in 1999 and is headquartered in Taipei city, Taiwan.
TSH Biopharm Corporation Limited Fundamentals Summary
| 8432 fundamental statistics | |
|---|---|
| Market cap | NT$2.48b |
| Earnings (TTM) | NT$87.98m |
| Revenue (TTM) | NT$931.86m |
28.2x
P/E Ratio2.7x
P/S RatioIs 8432 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8432 income statement (TTM) | |
|---|---|
| Revenue | NT$931.86m |
| Cost of Revenue | NT$454.65m |
| Gross Profit | NT$477.21m |
| Other Expenses | NT$389.23m |
| Earnings | NT$87.98m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.29 |
| Gross Margin | 51.21% |
| Net Profit Margin | 9.44% |
| Debt/Equity Ratio | 0% |
How did 8432 perform over the long term?
See historical performance and comparison